ArticleBlood cancer journal2025
Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort.
Abstract readValidation Study
In one paragraph
Article in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Clinicopathologic Characteristics of SomaticEJHaem · 2026Article
- Subclonal MECOM rearrangements in myeloid neoplasms: enriched for TP53 mutations and adverse outcome.Leukemia · 2026Article
- p53 Immunohistochemistry Is a Reliable Method for Assessing TP53 Allelic and Functional Status in TP53-Mutated Cases.American journal of hematology · 2026Article
- Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study.Leukemia · 2026Article
- A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions.Nature reviews. Clinical oncology · 2026Review
- Prognostic impact of intensive chemotherapy in patients with TP53-mutated AML.Blood cancer journal · 2026Article
- Discovery of BEND4 as a novel single-gene prognostic marker and therapeutic target for adverse AML.NPJ precision oncology · 2026Article
- Article
- Single-cell profiling reveals reprogrammed hierarchy and disrupted immune-stromal ecosystem in TP53-mutated AML.Experimental hematology & oncology · 2026Article
- AML, Myelodysplasia-Related: Beyond Classification-Toward Precision Decision-Making.Mediterranean journal of hematology and infectious diseases · 2026Review
- Coagulation activation is associated with genomic-instability-related features in TP53-mutated AML and MDS: routine laboratory patterns beyond classical disseminated intravascular coagulation.Frontiers in cell and developmental biology · 2026Article
- Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults.Blood cancer journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
37 authors.
Mithun Vinod ShahDivision of Hematology, Mayo Clinic, Rochester, MN, USA. shah.mithun@mayo.edu.ORCID http://orcid.org/0000-0002-5359-336X
Kevin HungDepartment of Haematology, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, SA, Australia.ORCID http://orcid.org/0009-0001-9354-5864
Anmol BaranwalDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-3432-0489
Gauri WechalekarDepartment of Haematology, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, SA, Australia.
Aref Al-KaliDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-0824-3715
Carla R ToopDepartment of Haematology, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, SA, Australia.
Patricia GreippLaboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Monika M KutynaDepartment of Haematology, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, SA, Australia.
Aasiya MatinDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Dariusz LadonGenetic and Molecular Pathology, SA Pathology, Adelaide, SA, Australia.
Antoine SalibaDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-5134-7336
Dong ChenDivision of Hematopathology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-7627-9560
Kebede BegnaDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0003-2730-8593
Anna BrownGenetic and Molecular Pathology, SA Pathology, Adelaide, SA, Australia.ORCID http://orcid.org/0000-0002-9023-0138
Danielle RudDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Mark R LitzowDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
William J HoganDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-5841-4105
Peter BardyDepartment of Haematology, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, SA, Australia.
Talha BadarDepartment of Hematology/Oncology, Mayo Clinic, Jacksonville, FL, USA.ORCID http://orcid.org/0000-0003-1548-918X
Sharad KumarCentre for Cancer Biology, University of South Australia and SA Pathology, Adelaide, SA, Australia.ORCID http://orcid.org/0000-0001-7126-9814
David T YeungDepartment of Haematology, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, SA, Australia.
Mrinal M PatnaikDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-6998-662X
James M ForanDepartment of Hematology/Oncology, Mayo Clinic, Jacksonville, FL, USA.ORCID http://orcid.org/0000-0003-1673-1708
Rong HeDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-6116-8163
Naseema GangatDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-9104-6172
Mehrdad HefaziDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-8860-3380
Hamish S ScottGenetic and Molecular Pathology, SA Pathology, Adelaide, SA, Australia.ORCID http://orcid.org/0000-0002-5813-631X
Cecilia Y Arana YiHematology/Oncology, Mayo Clinic, Scottsdale, AZ, USA.
Hassan AlkhateebDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-3609-8404
Abhishek A MangaonkarDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0003-2458-9887
Daniel ThomasDepartment of Haematology, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, SA, Australia.
Christopher N HahnGenetic and Molecular Pathology, SA Pathology, Adelaide, SA, Australia.ORCID http://orcid.org/0000-0001-5105-2554
Attilio OraziTexas Tech University Health Sciences Center, El Paso, TX, USA.ORCID http://orcid.org/0000-0002-1660-7013
Daniel A ArberUniversity of Chicago, Chicago, IL, USA.ORCID http://orcid.org/0000-0002-2160-9689
Chung Hoow KokAdelaide Medical School, University of Adelaide, Adelaide, SA, Australia.ORCID http://orcid.org/0000-0002-3181-7852
Ayalew TefferiDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0003-4605-3821
Devendra HiwaseDepartment of Haematology, Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, SA, Australia. devendra.hiwase@sa.gov.au.ORCID http://orcid.org/0000-0002-6666-3056
Funding
Department of Health | National Health and Medical Research Council (NHMRC) GNT2007739Department of Health | National Health and Medical Research Council (NHMRC) MRF1195517
Abstract
The World Health Organization (WHO-5) and International Consensus Classification (ICC) acknowledge the poor prognosis of TP53-mutated (TP53
Indexed as
Leukemia, Myeloid, AcuteMutationTumor Suppressor Protein p53AdultAgedAged, 80 and overConsensusFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesWorld Health OrganizationTP53 protein, humanTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.